山崎 聡

Medicine & Life Sciences

1. Cell Transplantation 100%
2. Allogeneic Cells 91%
3. Hematopoietic Stem Cell Transplantation 72%
4. Acute Myeloid Leukemia 63%
5. Japan 48%
6. Stem Cell Transplantation 47%
7. Graft vs Host Disease 44%
8. Fetal Blood 40%
9. Bortezomib 40%
10. Transplantation 39%
11. Transplants 38%
12. Human mastadenovirus F 38%
13. Peripheral T-Cell Lymphoma 36%
14. Multiple Myeloma 34%
15. Adult T Cell Leukemia Lymphoma 34%
16. Lymphoma 33%
17. Retrospective Studies 28%
18. Dexamethasone 28%
19. Survival 27%
20. Mantle-Cell Lymphoma 26%
21. Tissue Donors 23%
22. Adenoviridae 22%
23. T-Cell Lymphoma 21%
24. Lenalidomide 20%
25. Incidence 20%
26. GATA2 Deficiency 18%
27. mesothelin 17%
28. Rituximab 17%
29. Cytogenetics 16%
30. Lymphoma, Large B-Cell, Diffuse 15%
31. Leukemia 15%
32. Therapeutics 15%
33. Lymphoproliferative Disorders 15%
34. Elderly 15%
35. Recurrence 15%
36. Granulocyte Colony-Stimulating Factor 14%
37. gemcitabine 14%
38. Mortality 14%
39. Bone Marrow Transplantation 14%
40. Regulator Genes 13%
41. Hematologic Neoplasms 13%
42. Peripheral Blood Stem Cell Transplantation 13%
43. Mitogen-Activated Protein Kinases 13%
44. Human Herpesvirus 6 encephalitis 12%
45. Unrelated Donors 12%
46. mogamulizumab 12%
47. Follicular Lymphoma 12%
48. Haploidentical Transplantation 12%
49. Blood Cells 12%
50. Acquired Factor 8 deficiency 11%